Reported increased energy levels in trials
Reported value in published research relating to GLP-1 multi-agonist compounds.
Provided strictly as a scientific reference point.
Participants consumed fewer calories per day without being instructed to diet – driven by decreased appetite and satiety signaling.
Provided strictly as scientific context
Average weight loss during clinical trial period of 48 weeks on high-dose Retatrutide.
Example data point referenced in peer-reviewed studies for GLP-1 multi-agonists.
Alluvi does not promote or imply medical use of its products.
Reference value drawn from published research on GLP-1 multi-agonist compounds.
Provided strictly as scientific context.
Alluvi Peptides is a forward-thinking healthcare solutions provider dedicated to improving patient outcomes through a combination of advanced technology, clinical expertise, and compassionate care delivery. Built on a foundation of innovation and reliability, Alluvi Healthcare focuses on delivering high-quality medical services, products, and support systems that empower both healthcare professionals and patients alike.
Supplements
Supplements
Compound (R&D Only)
Compound (R&D Only)
Alluvi Peptides | Alluvi Tirzepatide 40mg peptide (R&D Only)
Compound (R&D Only)
Alluvi Peptides | Alluvi Tirzepatide 20mg peptide (R&D Only)
Compound (R&D Only)
Compound (R&D Only)
Compound (R&D Only)
